# 503A vs 503B Pharmacy: What's the Difference?

> 503A vs 503B pharmacy comes down to who writes the order and who oversees the facility. See how they differ and which one fits your telehealth program.

Source: https://www.fusehealth.com/blogs/503a-vs-503b-which-pharmacy-for-your-program

---
[Insights](https://www.fusehealth.com/blogs)/503A vs 503B Pharmacy: What's the Difference?

BlogCompliance & LegalPharmacyWhite LabelOperator Guide

FUSE Health · 12 min read · August 12, 2026

# 503A vs 503B Pharmacy: What's the Difference?

![503A vs 503B Which Pharmacy for Your Program - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/9f9253ce92ed94eb79ec9173788f105e7567c1b3-1600x900.webp?w=1600&q=75&auto=format)

TLDR

A 503A pharmacy compounds for one named patient under a state board. A 503B outsourcing facility registers with FDA, follows manufacturing standards and can supply office stock. Most telehealth programs end up using both, routed by state and product, so one rule change never stops the business.

## Executive Summary

A 503A pharmacy compounds for one named patient under a state board. A 503B outsourcing facility registers with FDA, follows manufacturing standards and can supply office stock. Most telehealth programs end up using both, routed by state and product, so one rule change never stops the business.

I get asked about 503A vs 503B pharmacy on nearly every operator call we run at FUSE. Most founders treat the 503A vs 503B question as a pharmacy detail to sort out after launch. It decides which states you can sell into, whether product can sit on a shelf before an order exists, and how much time you get when a federal rule changes.

Both models are legal, and both compound medication, so the 503A vs 503B choice is a question of fit. They answer to different regulators, and that single difference shows up in your launch timeline, your catalog and your risk. Below you'll find the plain-English version, the legal framing and a clear read on which model fits which kind of program.

One note on words. People search for "503B pharmacy," so you'll see that phrase here too. FDA's own term is [outsourcing facility](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities), and the law treats those sites differently from pharmacies.

## 503A vs 503B Pharmacy: The Quick Comparison

| Comparison point | 503A                                                                    | 503B                                                                                                          |
| ---------------- | ----------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------- |
| What it is       | Traditional compounding pharmacy, licensed by a state board of pharmacy | Outsourcing facility registered with FDA                                                                      |
| Who it serves    | Individual patients, one prescription at a time                         | Providers and healthcare facilities that need product on hand, plus individual patients                       |
| Main distinction | Compounds from a patient-specific prescription                          | May produce batches without a patient-specific prescription, under manufacturing standards and FDA inspection |

The rest of this 503A vs 503B pharmacy guide unpacks each row.

See the pharmacy layer before you commit. [Book a walkthrough](https://www.fusehealth.com/brands) and we'll show you how orders route across 503A and 503B partners.

## What Is a 503A Pharmacy?

So, what is a 503A pharmacy? It is a traditional compounding pharmacy. The name points to [Section 503A](https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies) of the Federal Food, Drug, and Cosmetic Act, which lets a state-licensed pharmacy compound medication without going through FDA drug approval, as long as it meets a list of conditions. A licensed pharmacist runs the compounding, and the state board of pharmacy is the day-to-day regulator.

![What Is a 503A Pharmacy - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/8c78c88723242907aef9d861d1f77bd7ca31b778-1600x900.webp)

The Drug Quality and Security Act of 2013 ([DQSA](https://www.congress.gov/bill/113th-congress/house-bill/3204)) rewrote 503A and created 503B. Congress acted after a contaminated steroid injection from a single compounding pharmacy set off a fungal meningitis outbreak that reached [750 cases](https://epi.dph.ncdhhs.gov/cd/meningitis/MultistateFungalInfectionOutbreak%5FNCFinalReport.pdf) and 64 deaths across 20 states by September 2013\. That history explains why two categories exist and why regulators care which one a 503A pharmacy or 503B facility falls under.

### How a 503A Pharmacy Fills an Order

Your prescriber evaluates a patient and writes a prescription with that patient's name on it. The pharmacy compounds that prescription, labels it for that person and ships it. Working from a named patient is the legal backbone of 503A.

These pharmacies follow USP compounding standards plus any extra rules their state board adds. FDA exempts them from current good manufacturing practice, usually shortened to CGMP, which is the factory-grade standard 503B facilities follow.

### What Limits a 503A Pharmacy

- Office stock is mostly off the table. With narrow exceptions, the pharmacy compounds after a prescription exists, so it can't build inventory for a clinic shelf.
- The ingredient needs a pedigree. A bulk drug substance has to meet a USP or NF monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list.
- Copies of approved drugs are restricted. A pharmacy can't regularly compound essentially copies of a commercially available drug, and it needs a documented clinical reason for an individual patient when it does.
- Geography takes paperwork. Shipping into a state generally means holding that state's nonresident license, and federal law adds an [interstate cap](https://www.frierlevitt.com/articles/compounded-drug-distribution-mou-between-fda-and-the-states/) of 5% of prescriptions unless the pharmacy's home state signed a memorandum of understanding with FDA. Your counsel should confirm how that cap is being applied today.

## What Is a 503B Outsourcing Facility?

![What Is a 503B Facility - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/3a09e0493965b74e189a8e501a0d9a3f9cc953fc-1600x900.webp)

A 503B outsourcing facility is a compounder that chooses to register with FDA under Section 503B. Registration is voluntary, and it comes with strings that change how the facility works day to day.

### What FDA Registration Changes

- Product can ship without a patient name. A facility can make batches and supply providers with office stock, or fill an individual prescription when that's what's ordered.
- CGMP applies. That's the manufacturing standard covering the facility, equipment, testing and batch records.
- FDA inspects on a risk-based schedule. The facility reports adverse events and sends FDA product reports twice a year, and FDA publishes a [list of registered facilities](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities) you can check before you sign.

### Where a 503B Facility Runs Out of Room

The ingredient menu is narrower. Generally, a 503B facility can use bulk substances on FDA's 503B bulks list, drugs on FDA's shortage list, or components of approved drugs. A newer substance can be available at a 503A pharmacy and unavailable at a 503B facility.

Federal policy can also target one side. When HHS announced its interim enforcement policy for six peptides on October 28, 2026, it covered 503A compounding and left 503B facilities out. [Our HHS explainer](https://www.fusehealth.com/blogs/peptide-compounding-hhs-policy-explained) walks through all ten conditions, and the policy is still a draft that HHS can revise.

## 503A vs 503B Differences Side by Side

Here is the detailed 503A vs 503B pharmacy view for operators and counsel who want every row.

| Factor                 | 503A pharmacy                                                                                          | 503B outsourcing facility                                                                   |
| ---------------------- | ------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------- |
| Main regulator         | State board of pharmacy                                                                                | FDA, plus state licensure                                                                   |
| Prescription           | Patient-specific prescription required                                                                 | Not required for office stock                                                               |
| Manufacturing standard | USP compounding standards                                                                              | CGMP                                                                                        |
| FDA inspection         | Not on a routine schedule                                                                              | Risk-based schedule                                                                         |
| FDA reporting          | Limited                                                                                                | Adverse events plus twice-yearly product reports                                            |
| Out-of-state shipping  | State licenses, and the federal interstate cap applies unless the home state signed the FDA memorandum | Federal registration; interstate cap does not apply; state licensure still needs confirming |
| Ingredient menu        | Broader: USP or NF monograph, approved-drug component or 503A bulks list                               | Narrower: 503B bulks list, shortage list or approved-drug component                         |

### Where 503A and 503B Overlap

In any 503A vs 503B comparison, both are legal, and both come from the same 2013 law. Both are barred from compounding essentially copies of approved drugs outside narrow exceptions. Federal registration doesn't replace state licensure either, so a 503B facility still has to be licensed in the states that require it.

### A Simple Way to Remember 503A vs 503B

503A starts with a patient. 503B can start with a provider's order. Everything else in the table follows from that.

## Why Telehealth Businesses Need to Understand 503A vs 503B

Your pharmacy partner holds either 503A or 503B status, and your catalog, your state coverage and your refill logic all inherit what that partner is allowed to do. In our experience, operators who learn this after launch end up rebuilding pieces that were already live.

### It Decides Which States You Can Serve

Each state your patients live in has a say. A 503A pharmacy shipping out of state needs the right license in each one, and licensing timelines vary from state to state. A 503B facility ships under federal registration, though state rules still apply. If you're mapping expansion, start with our guides to [pharmacy licensing](https://www.fusehealth.com/blogs/telehealth-pharmacy-licensing) and to selling [across state lines](https://www.fusehealth.com/blogs/which-states-allow-telehealth-across-state-lines).

### It Sets How Much Time You Get When a Rule Changes

GLP-1 drugs are the cleanest example. FDA resolved the tirzepatide shortage on December 19, 2024 and the semaglutide shortage on February 21, 2025\. Compounding of both had leaned on shortage status, and [FDA's statement](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) set end dates that differed by designation.

| Drug        | 503A pharmacies stopped | 503B facilities stopped |
| ----------- | ----------------------- | ----------------------- |
| Tirzepatide | March 5, 2025           | March 19, 2025          |
| Semaglutide | April 24, 2025          | May 22, 2025            |

On semaglutide, 503B facilities got four weeks longer than 503A pharmacies. Operators on one designation found out which side of that gap they were standing on. Today both drugs sit under the copies rule, which we cover in our guides to [compounded semaglutide](https://www.fusehealth.com/blogs/how-compounded-semaglutide-programs-work-through-telehealth) and [compounded tirzepatide](https://www.fusehealth.com/blogs/compounded-tirzepatide-vs-zepbound-operator-guide).

### It Puts the Pharmacy on Your Risk List

When FDA or a state board has a question about a compounded product, the pharmacy gets the first call and you get the second. Your intake, your marketing claims and your refill timing all sit on top of what the pharmacy may legally do. That's why we treat choosing a [pharmacy partner](https://www.fusehealth.com/blogs/choose-right-white-label-pharmacy) as a launch decision.

## Which Pharmacy Model Fits Your Program

Choosing between 503A vs 503B comes down to program shape. The scenarios below are illustrations rather than client stories, and they show how the designation lines up with the shape of a program.

### One Location in One State

A med spa in Dallas that sees Texas patients in person and follows up by video works inside one state board's rules. A 503A pharmacy fits that setup well because your prescriber writes for the patient in front of them. Add a second state later and the licensing question comes with it, so map that before you spend on ads outside Texas. Our guide for [med spas](https://www.fusehealth.com/blogs/how-med-spas-sell-peptides-online) covers the setup.

### Several Locations Across States

A group with clinics in Chicago, Atlanta and Boston has three state boards in play. Many groups keep a 503A pharmacy for patient-specific orders and add a 503B facility where in-clinic supply or batch consistency matters. Which products go where depends on the ingredient menus in the table above.

### A National Telehealth or Creator Brand

A wellness creator in Los Angeles or a telehealth startup in New York gets patients from everywhere. Each prescription needs a pharmacy licensed for that patient's state, and most direct-to-patient volume runs through 503A pharmacies holding nonresident licenses. Add a 503B facility where its ingredient menu and batch documentation fit. Pharmacy routing holds this together, and our pieces on [pharmacy routing](https://www.fusehealth.com/blogs/glp-1-pharmacy-routing-telehealth) and how [D2C brands](https://www.fusehealth.com/use-case/how-d2c-brands-launch-white-label-telehealth) launch show how.

### Programs Built Around Peptides

Peptide programs follow their own track. Under the October 2026 HHS policy, a 503A pharmacy can compound six named peptides for a named patient when ten conditions hold, and 503B facilities can't fill them under it. Peptides outside that list keep the status they had before, which our [Category 2 list](https://www.fusehealth.com/blogs/white-label-peptides-fda-category-2-list) and [legal peptides](https://www.fusehealth.com/blogs/which-peptides-are-legal-operator-guide) guide follow.

## How to Vet a 503A or 503B Partner

Whether your partner is a 503A pharmacy or a 503B facility, run the same short checklist before you sign. Our [pharmacy comparison](https://www.fusehealth.com/blogs/white-label-pharmacy-comparison-guide-for-operators) guide goes deeper on scoring partners side by side.

### Six Checks Before You Sign

1. Get the designation in writing, product by product. A company can run a 503A pharmacy and a 503B facility under one name, and each product has to match the right one.
2. Confirm the license or registration. Look up 503A pharmacies at the state board of pharmacy and 503B facilities on [FDA's list](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities).
3. Ask for inspection history. For a 503B facility that means FDA inspection findings, Form 483 observations and warning letters. For a 503A pharmacy, ask for state board findings.
4. Request a sample certificate of analysis for every product you plan to list.
5. Confirm shipping coverage state by state, plus how the partner handles recalls and adverse event reports.
6. Line up a second partner. Single-source operators stall when a product changes category or a facility draws a finding.

### Red Flags That Should Slow You Down

- A partner that won't share inspection history or certificates of analysis.
- Anyone who calls a compounded product FDA-approved. [FDA states](https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies) that compounded drugs aren't FDA-approved.
- A shipping list that doesn't match the states you plan to sell into.
- One facility carrying every product, with no named backup.

## What Operators Get Wrong About 503A vs 503B

The same four 503A vs 503B mistakes show up again and again in the programs we talk to. Each one has a fix you can put in place before launch.

### Four Mistakes and What Works Instead

| Mistake                                            | What works instead                                                          |
| -------------------------------------------------- | --------------------------------------------------------------------------- |
| Treating the designation as the pharmacy's problem | Map your states, catalog and refills to what the partner is licensed to do  |
| Assuming a 503B facility can make anything         | Check each ingredient against the 503B lists before it goes in your catalog |
| Signing one pharmacy with no backup                | Route across at least two partners with different strengths                 |
| Treating an interim federal policy as final        | Build the catalog so pulling one product is a settings change               |

### Why Backup Routing Matters

When a facility draws an inspection finding or a product changes category, every order tied to it waits. A second partner turns a halted program into a rerouted one. Our [pharmacy integration](https://www.fusehealth.com/use-case/telehealth-pharmacy-integration-before-you-launch) page shows what to set up before launch.

## How FUSE Routes Orders Across 503A and 503B Partners

FUSE is the infrastructure layer behind your brand, and 503A and 503B pharmacy partners sit inside it. You own the storefront, the pricing and the customer relationship, and the clinical and pharmacy steps run behind it.

### The Order Path

1. Your customer completes a structured intake on your branded storefront.
2. An independent licensed clinician in the customer's state reviews it, then approves, adjusts or declines.
3. The order is checked against the customer's state.
4. Approved prescriptions route to a 503A or 503B partner based on product and jurisdiction, and the pharmacy ships to the named patient.

### What Holds Up as Volume Grows

Licensed providers cover all 50 states, and pharmacy partners on both designations sit behind a single routing layer. If a partner has a problem, the order path changes and your storefront stays put. You can see the full sequence on [how it works](https://www.fusehealth.com/how-this-works), and the [peptide telehealth](https://www.fusehealth.com/peptide-telehealth) page shows the same layer applied to peptide programs.

## The Bottom Line on 503A vs 503B Pharmacy

![503A vs 503B - The Bottom Line - FUSE](https://cdn.sanity.io/images/yd6yvgd6/production/4fe8170086b4224832f7093d065daff41a83dfa4-1600x900.webp)

503A starts with a patient and a prescription. 503B can start with a provider's order. Most telehealth programs use both, because patients live in many states and each product has its own legal path. Settle your 503A vs 503B pharmacy mix before launch and you set your own timeline.

If you want a second set of eyes on yours, [book a consultation](https://www.fusehealth.com/brands) and we'll map your states, your catalog and the pharmacy routing that keeps launch day from waiting on a pharmacy.

_This article is general information for healthcare business operators. It isn't legal or medical advice, it doesn't recommend any treatment, and it can't replace advice from your own counsel and pharmacy partner. Independent licensed clinicians make every prescribing decision on programs powered by FUSE. Rules in this area change, so confirm each point before you act on it._

## References

1. [FDA. Compounding Laws and Policies.](https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies)
2. [FDA. Registered Outsourcing Facilities under Section 503B of the FD&C Act.](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)
3. [FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize)
4. [Congress.gov. H.R. 3204, Drug Quality and Security Act (113th Congress).](https://www.congress.gov/bill/113th-congress/house-bill/3204)
5. [North Carolina Division of Public Health. Multistate Fungal Infection Outbreak: North Carolina Final Report.](https://epi.dph.ncdhhs.gov/cd/meningitis/MultistateFungalInfectionOutbreak%5FNCFinalReport.pdf)
6. [CDC. Multistate Outbreak of Fungal Infection Associated with Injection of Methylprednisolone Acetate Solution from a Single Compounding Pharmacy, United States, 2012\. MMWR.](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm61e1012a1.htm)
7. [Frier Levitt. Compounded Drug Distribution MOU Between FDA and the States.](https://www.frierlevitt.com/articles/compounded-drug-distribution-mou-between-fda-and-the-states/)
8. [Federal Register. Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products, May 14, 2020.](https://www.govinfo.gov/content/pkg/FR-2020-05-14/pdf/2020-10336.pdf)
9. [HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B.](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)
10. [Federal Register. Doc. 2026-22192, Docket No. HHS-OASH-2026-0496.](https://www.federalregister.gov/d/2026-22192)
11. [Fagron Sterile Services. 503A Compounding Pharmacies vs. 503B Outsourcing Facilities: Similarities and Differences.](https://www.fagronsterile.com/newsroom/503a-vs-503b-compounding-pharmacies)
12. [The FDA Group. 503A vs. 503B: A Quick Guide to Compounding Pharmacy Designations and Regulations.](https://www.thefdagroup.com/blog/503a-vs-503b-compounding-pharmacies)

![Daniel Meursing](https://cdn.sanity.io/images/yd6yvgd6/production/ef49a0c35413d503a60b98969aa02be40a9dab28-1200x632.jpg)

Daniel Meursing

CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.

Background

Startup Operations & Service Systems

Experience

2x Founder, Multi-Market U.S. Scaling

Qualifications

Healthtech Market Expertise & Operational Scaling

Key Achievement

Scaled Premier Staff & Eventstaff across major U.S. markets

## Frequently Asked Questions

### What is the difference between a 503A and a 503B pharmacy?

A 503A pharmacy is a state-licensed compounding pharmacy that compounds for a named patient on a valid prescription, overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with FDA, follows CGMP, is inspected on a risk-based schedule and can supply providers with product without a patient-specific prescription. The Drug Quality and Security Act of 2013 created that split.

### Is a 503B facility better than a 503A pharmacy?

In the 503A vs 503B pharmacy debate, neither wins outright. A 503A pharmacy fits patient-specific orders and offers a broader ingredient menu. A 503B facility fits batch supply, office stock and manufacturing-grade documentation, with a narrower menu. Most multi-state telehealth programs end up using both.

### Can a 503A pharmacy ship to patients in other states?

Often yes. The pharmacy needs a license in each state it ships into, every order still needs a patient-specific prescription, and the federal interstate cap applies unless its home state signed the FDA memorandum. That works across a few states. Across national demand it becomes a licensing project, which is where routing across several pharmacies helps.

### Can 503A or 503B pharmacies still compound semaglutide or tirzepatide?

Only within tight limits. The shortages that allowed broad compounding ended in December 2024 and February 2025, and the enforcement windows closed in 2025\. A pharmacy can still compound a drug that is essentially a copy of an approved one only when the prescriber documents a clinical difference for an individual patient, and never regularly or in inordinate amounts. Ask your partner to show the legal basis in writing.

### How do I verify a 503B partner is legitimate?

Check that the facility appears on FDA's list of registered outsourcing facilities. Then ask for its inspection history, any Form 483 observations, and how it handles recalls and adverse event reporting. Confirm which states it's licensed to ship into, since federal registration doesn't replace state licensure.

Ready to act on this?

- [Launch your own brandSee how brands go live on FUSE.](https://www.fusehealth.com/brands)
- [Join as a providerSee how clinicians work with FUSE brands.](https://www.fusehealth.com/provider)
- [See pricingEvery plan and fee, published.](https://www.fusehealth.com/pricing)

 In this guide

- [Executive Summary](#header-1)
- [503A vs 503B Pharmacy: The Quick Comparison](#header-2)
- [What Is a 503A Pharmacy?](#header-3)
- [What Is a 503B Outsourcing Facility?](#header-4)
- [503A vs 503B Differences Side by Side](#header-5)
- [Why Telehealth Businesses Need to Understand 503A vs 503B](#header-6)
- [Which Pharmacy Model Fits Your Program](#header-7)
- [How to Vet a 503A or 503B Partner](#header-8)
- [What Operators Get Wrong About 503A vs 503B](#header-9)
- [How FUSE Routes Orders Across 503A and 503B Partners](#header-10)
- [The Bottom Line on 503A vs 503B Pharmacy](#header-11)
- [Frequently Asked Questions](#faq)

Launch faster

Go live with a compliant, branded peptide program — prescribing, pharmacy, and providers included.

Share

[](https://x.com/intent/post?url=https%3A%2F%2Fwww.fusehealth.com%2Fblogs%2F503a-vs-503b-which-pharmacy-for-your-program&text=503A%20vs%20503B%20Pharmacy%3A%20What's%20the%20Difference%3F)[](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.fusehealth.com%2Fblogs%2F503a-vs-503b-which-pharmacy-for-your-program)

## Recent Posts

[Compounded Tirzepatide vs Zepbound: An Operator GuideFUSE Health · 8 min read](https://www.fusehealth.com/blogs/compounded-tirzepatide-vs-zepbound-operator-guide)[Asynchronous Telehealth: The State Rules and WorkflowFUSE Health · 8 min read](https://www.fusehealth.com/blogs/asynchronous-telehealth-state-rules-and-workflow)[Telehealth Pharmacy Licensing: Why Programs Get StuckFUSE Health · 9 min read](https://www.fusehealth.com/blogs/telehealth-pharmacy-licensing)[White Label Peptides: The Current FDA Category 2 ListFUSE Health · 9 min read](https://www.fusehealth.com/blogs/white-label-peptides-fda-category-2-list)

## Building a Peptide Brand?

See how FUSE infrastructure can help you launch and scale a compliant program faster.
